ストックスクリーナーアプリを入手
0.5231
1.49%
-0.0079
アフターアワーズ：
.50
-0.0231
-4.42%
前日終値:
$0.531
開ける：
$0.5195
24時間の取引高:
33,409
Relative Volume:
0.05
時価総額：
$4.32M
収益：
-
当期純損益:
$-10.31M
株価収益率:
-0.2244
EPS:
-2.3308
ネットキャッシュフロー:
$-6.32M
1週間 パフォーマンス:
-13.09%
1か月 パフォーマンス:
+2.31%
6か月 パフォーマンス:
-14.67%
1年 パフォーマンス:
-64.66%
1日の値動き範囲:
$0.51
$0.531
1週間の範囲:
$0.51
$0.60
52週間の値動き範囲:
$0.4111
$1.65
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Compare GLMD vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.5231 | 4.63M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-05-22 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 開始されました | Craig Hallum | Buy |
| 2020-01-30 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-08-02 | 繰り返されました | Maxim Group | Buy |
| 2018-07-13 | 開始されました | Stifel | Buy |
| 2018-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-15 | アップグレード | Maxim Group | Hold → Buy |
| 2018-02-14 | ダウングレード | Maxim Group | Buy → Hold |
| 2018-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-15 | 開始されました | ROTH Capital | Buy |
| 2017-08-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 繰り返されました | Maxim Group | Buy |
| 2016-08-01 | 繰り返されました | Maxim Group | Buy |
| 2016-07-06 | 再開されました | ROTH Capital | Buy |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-23 | 開始されました | H.C. Wainwright | Buy |
| 2015-05-06 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
すべてを表示
Galmed Pharmaceuticals Ltd (GLMD) 最新ニュース
Galmed Pharmaceuticals to Enact 1-for-8 Reverse Share Split Effective August 19, 2026 - TipRanks
Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026 - Stock Titan
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2026 Earnings: Surprise Profit Driven by Expense Management and Non-Operating GainsEarnings Power Value - dars.gov.et
GLMD Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
Galmed advances Parkinson’s drug formulation with higher CNS exposure - Investing.com
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PR Newswire
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.602|Chg%:-0.004 - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.523|Chg%:-0.008 - TradingKey
Galmed Pharmaceuticals (GLMD) Slides 5.4%: Testing Key Support After Bearish MoveSign of Weakness - dars.gov.et
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - The Globe and Mail
Galmed Pharmaceuticals (GLMD) sets 2026 AGM on name change and pay - Stock Titan
Galmed unveils heart-targeted Aramchol in cardiac fibrosis push - Indian Pharma Post
Galmed Accelerates Heart Failure Innovation with Aramchol - t.co
Galmed develops heart-targeted formulation of Aramchol drug By Investing.com - Investing.com South Africa
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) - Yahoo Finance
Galmed develops heart-targeted formulation of Aramchol drug - Investing.com
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs - Stock Titan
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol - PR Newswire
Galmed Pharmaceuticals (GLMD) Sheds 4.75% as Biotech Volatility Pressures Near SupportPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals (GLMD) Holds Steady at $0.57: Consolidation Phase with Key Levels in FocusSkew Index - dars.gov.et
Galmed Pharmaceuticals Reports Wider Q1 2026 Loss Amid Higher R&D Spending - TipRanks
Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition - Stock Titan
GLMD|Galmed Pharmaceuticals Ltd|Price:0.513|Chg%:-0.040 - TradingKey
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - AOL.com
Galmed Pharmaceuticals (GLMD) Plunges Nearly 12% as Stock Tests Key Support at $0.54Trading Ideas - dars.gov.et
Galmed Pharmaceuticals (GLMD) Slides 12% as Selling Pressure Intensifies Near Key SupportMarket Neutral Pair - dars.gov.et
Galmed Pharmaceuticals Ltd. (GLMD) Q4 2025 Earnings: EPS Miss Extends Losses as Pre‑Revenue Biotech Faces Pipeline UncertaintyShare Repurchase Impact - dars.gov.et
GLMD Forecast — Price Target — Prediction for 2027 - TradingView
GLMD Should I Buy - Intellectia AI
Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD) - TradingView
GPH Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to book forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to sales forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure - The Globe and Mail
Galmed completes acquisition of medical device firm Colospan - Investing.com UK
Galmed Pharmaceuticals finishes restructured Colospan deal - grafa.com
Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd. - TradingView
Galmed completes acquisition of medical device firm Colospan By Investing.com - Investing.com Nigeria
Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout - Stock Titan
Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout - Stock Titan
Galmed Pharmaceuticals Ltd (GLMD) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):